New Analysis of 13,560 Patients Demonstrates DecisionDx®-Melanoma Stratifies Risk Across Histological Subtypes; Findings to be Presented at Fall Clinical Dermatology Conference

Core Insights - Castle Biosciences is presenting data on its DecisionDx®-Melanoma test and pipeline atopic dermatitis gene expression profile test at the 25th Annual Fall Clinical Dermatology Conference [1] - The DecisionDx-Melanoma test has shown clinically significant risk stratification across various histological subtypes of melanoma, confirming its clinical value [2][4] - The pipeline atopic dermatitis test aims to improve treatment decision-making by classifying patients based on their underlying disease biology [5] DecisionDx-Melanoma Insights - The DecisionDx-Melanoma test utilizes a 31-gene expression profile to stratify melanoma-specific survival across different tumor subtypes, demonstrating significant differences in five-year survival rates [4][6] - In a cohort of 13,560 patients, five-year melanoma-specific survival was 98.5% for Class 1A (lowest risk) and 82.3% for Class 2B (highest risk) patients with nodular melanoma [4] - The test can identify early-stage melanoma patients at higher risk of distant metastasis, with Class 2B patients showing significantly higher rates of metastasis compared to Class 1A patients [4] Atopic Dermatitis Pipeline Insights - The pipeline atopic dermatitis test classifies patients into Th2 Molecular Profile or JAKi Responder Profile, aiming to guide systemic therapy selection [5] - Data indicates that patients with a JAKi responder profile experience rapid and deep responses to JAK inhibitors, potentially improving treatment outcomes [5] - The test seeks to shift atopic dermatitis care from trial-and-error prescribing to more personalized treatment approaches, enhancing patient satisfaction and reducing healthcare costs [5] Company Overview - Castle Biosciences is a diagnostics company focused on innovative tests that guide patient care, with a portfolio that includes tests for skin cancers and other diseases [7][8] - The company has conducted over 210,000 orders for the DecisionDx-Melanoma test, indicating strong market adoption and clinical relevance [6]